Login
Denali Therapeutics Inc. logo

Denali Therapeutics Inc.

denalitherapeutics.com

What Do They Do?

Develops medicines designed to carry large molecules across the blood-brain barrier for people with neurodegenerative, lysosomal storage and other serious diseases.

Who Are Their Customers?

Denali collaborates with biopharmaceutical companies and other research partners to develop and commercialize candidates. For approved candidates, it plans to sell in key markets itself and/or use partners or distributors.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▲ Turned profitable
vs −$126.9M in Q3 FY2025
  • Aug 6, 2026 Denali projected third-quarter AVLAYAH net product revenue of $10.0 million to $12.0 million
  • Apr 3, 2026 Takeda ended its DNL593 collaboration, returning program rights to Denali Denali said it would continue development independently.

From plans to launch preparation The older report described internal manufacturing and commercial infrastructure as capabilities to build in stages; the latest says a clinical manufacturing facility is open and commercial readiness is in place for tividenofusp alfa.

Who Do They Compete With?

Competes with Biogen, Eisai, Eli Lilly, Arrowhead, Roche, AbbVie, Bristol Myers Squibb, Prothena, Regeneron, Alnylam, BioArctic, Ionis, AstraZeneca, Takeda, Neuron23, Passage Bio, AviadoBio, Vesperbio, Arkuda Therapeutics, and Orchard Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support